Sera Prognostics Inc-A (NASDAQ:SERA) Reports Mixed Q2 2025 Results: EPS Beat Offsets Revenue Miss

Sera Prognostics Inc-A (NASDAQ:SERA) Reports Q2 2025 Earnings: Revenue Misses, EPS Beats Estimates

Sera Prognostics Inc., a company specializing in maternal and neonatal health diagnostics, released its second-quarter 2025 financial results, revealing mixed performance relative to analyst expectations. While the company’s earnings per share (EPS) came in better than anticipated, revenue fell significantly short of forecasts. The market reaction has been cautiously positive in after-hours trading, with shares rising approximately 1.8%.

Key Financial Highlights

• Revenue Miss: Reported revenue for Q2 2025 was $20,000, far below the analyst consensus estimate of $66,300. This represents a substantial shortfall, raising questions about near-term commercial execution.
• EPS Beat: The company posted a loss of $0.16 per share, which was better than the expected loss of $0.2295. This suggests that despite weak sales, cost management may have helped mitigate losses.
• Full-Year Estimates: Analysts project full-year 2025 revenue at $377,400, with an estimated EPS loss of $0.9078. For Q3, expectations stand at $137,700 in revenue and an EPS loss of $0.2397.

Market Reaction

The stock’s after-hours gain of 1.8% indicates a modestly positive response, likely driven by the narrower-than-expected loss. However, the steep revenue miss could weigh on sentiment in the longer term if commercial traction remains sluggish. Over the past month, shares have been relatively flat (+3.4%), while the two-week performance shows a decline of -11.6%, reflecting uncertainty ahead of earnings.

Press Release Summary

The earnings announcement emphasized Sera Prognostics’ focus on advancing maternal and neonatal health through its proprietary PreTRM test, a blood-based biomarker test designed to predict preterm birth risk. While no explicit forward guidance was provided, the company reiterated its commitment to expanding clinical adoption of its diagnostic solutions.

Outlook and Analyst Expectations

Given the lack of formal guidance in the press release, investors will likely scrutinize upcoming quarters to see if revenue trends improve toward the full-year estimate of $377,400. The Q3 revenue forecast of $137,700 will be a key benchmark for assessing whether the Q2 miss was an anomaly or indicative of broader challenges.

For a deeper dive into Sera Prognostics’ earnings and analyst estimates, visit the earnings page.

Disclaimer: This article is for informational purposes only and does not constitute investment advice. Investors should conduct their own research or consult a financial advisor before making any decisions.